Glox Therapeutics Raises £4.3M Seed Funding to Pioneer Precision Antimicrobials Targeting Drug-resistant Bacteria
Glox Therapeutics has raised £4.3 million for developing precision antibiotic therapies using engineered bacteriocins to combat antibiotic-resistant bacteria.